Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease
1.00 hr(s) | CME , MOC , ABIM
Therapeutic Area(s): Oncology , Dermatology
Release Date: June 15, 2021
Expiration Date: June 15, 2021
Location: Live Webcast
Immunotherapy has come to define the modern management model for malignant melanoma. Long-term evidence supports the use of PD-1 and CTLA-4 checkpoint inhibitors in unresectable, advanced/metastatic melanoma, while evidence from the adjuvant setting has confirmed immunotherapy’s role in resectable disease. Thus, immune checkpoint inhibitors and BRAF/MEK combinations for BRAF-mutant disease represent a platform on which to build further advances in melanoma care. New data suggest continued progress on several fronts, including novel PD-1–based combinations in advanced disease, neoadjuvant immunotherapy, and the potential of adjuvant immunotherapy in stage II melanoma.